Terminal Sterilization Services Global Market Report 2024

The terminal sterilization services market has grown rapidly in recent years. It will grow from $11.62 billion in 2023 to $12.9 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. The growth observed in the historical period can be credited to the heightened stringency of regulatory standards, an upsurge in healthcare expenditure, a rising demand for sterile medical devices, an increased number of surgical procedures, and the globalization of pharmaceutical manufacturing.

The terminal sterilization services market is expected to see rapid growth in the next few years. It will grow to $20.23 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The anticipated growth in the forecast period can be ascribed to the swift expansion of the biopharmaceutical industry, the increasing demand for the sterilization of single-use medical devices, a concentrated emphasis on outsourcing sterilization processes, a surge in contract sterilization services, the globalization of medical device manufacturing, and an elevated adoption of sterile packaging. Noteworthy trends expected in the forecast period encompass an uptick in outsourcing practices, continuous advancements in sterilization technologies, a heightened emphasis on single-use devices, strict adherence to regulatory compliance, and an increased focus on environmental sustainability.

The anticipated rise in hospital-acquired infections is poised to drive the growth of the terminal sterilization services market. Hospital-acquired infections, also known as healthcare-associated infections, are infections acquired during a hospital stay and are not present or in incubation at the time of admission. Terminal sterilization is a crucial process in hospitals, particularly for disposable medical devices and instruments used in patients, to prevent contamination and safeguard patients from healthcare-associated infections. For example, as of May 2022, reports from the World Health Organization (WHO) revealed that more than 24% of patients globally were affected by healthcare-associated infections. Additionally, the Centers for Disease Control and Prevention (CDC) in the US estimated that hospital-acquired infections resulted in about 1.7 million infections and 99,000 associated deaths annually, constituting 32% of all healthcare-acquired infections in the US by 2022. These numbers are expected to increase in the future, underscoring the driving force behind the terminal sterilization services market.

The increasing prevalence of chronic diseases is also poised to contribute to the growth of the terminal sterilization services market. Chronic diseases are persistent and often incurable health conditions requiring ongoing management and care. Terminal sterilization services play a crucial role in preventing infections and ensuring safety in managing medical equipment and supplies for individuals with chronic diseases. As of September 2022, according to the World Health Organization (WHO), non-communicable diseases (NCDs) or chronic diseases accounted for 74% of the 41 million deaths globally each year. This included 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Additionally, a report from the National Institutes of Health (NIH) in 2023 predicted a 99.5% increase in the number of people aged 50 and older with at least one chronic illness, rising from 71.522 million in 2020 to 142.66 million in 2050. Thus, the increasing prevalence of chronic diseases is a significant driver for the terminal sterilization services market.

Prominent companies in the terminal sterilization services market are concentrating on the development of advanced solutions, such as next-generation Vaporized Hydrogen Peroxide (VHP) systems such as VHP Biodecontamination Systems, in response to evolving needs. Vaporized Hydrogen Peroxide (VHP) bio-decontamination systems represent cutting-edge technologies engineered to achieve a substantial reduction in bioburden. For instance, in September 2021, Steris, a US-based provider of products and services supporting patient care, introduced the VHP 100i and 1000i vaporized hydrogen peroxide biodecontamination systems. These systems are designed for a 6-log reduction in bioburden in pharmaceutical, medical device, and research settings. Their seamless integration into building automation and HVAC systems facilitates convenient and frequent decontamination of diverse environments. In contrast to fogging systems, Steris VHP utilizes a dry, small-molecule process compatible with various surface materials, including sensitive electronic equipment.

Leading companies in the terminal sterilization services market are actively engaged in the development of advanced technologies, such as Lidding technology, to address challenges associated with heat sterilization. Lidding technology involves sophisticated methods and materials for designing and manufacturing lids or coverings in packaging applications. For example, in August 2021, Amcor, a Switzerland-based packaging company, unveiled innovative healthcare lidding technology for combination products, developed in collaboration with Johnson & Johnson Vision. This proprietary solution, based on patented inert film development, enables heat sterilization without drug uptake into the packaging. Particularly suitable for devices with Active Pharmaceutical Ingredients (API), the technology ensures machinability, post-sterilization integrity, and a patient-friendly peel opening.

In May 2023, Sharp, a Japan-based provider of commercial pharmaceutical packaging and clinical trial supply services, completed the acquisition of Berkshire Sterile Manufacturing (BSM) for an undisclosed amount. Through this strategic move, Sharp aimed to enhance its capabilities and offer a comprehensive, integrated solution in small-to-medium scale sterile injectable services. Berkshire Sterile Manufacturing (BSM), a US-based manufacturer of small-scale sterile clinical and commercial drug products, also provides terminal steam sterilization services.

Major companies operating in the terminal sterilization services market report are Steris plc, Getinge Group, Advanced Sterilization Products Services Inc., 3M Company, Belimed AG, Sterigenics International LLC, TSO3 Inc., Olympus Corporation, Matachana Group, Andersen Sterilizers Inc., Steelco S.P.A, Fedegari Group, Sotera Health Co., E-BEAM Services Inc., BGS Beta-Gamma-Service GmbH & Co. KG, Stryker Corporation, Medistri SA, Noxilizer Inc., H.W.Andersen Products Ltd., Cosmed Group, Cretex Companies Inc., Life Science Outsourcing Inc., MICROTROL Sterilisation Services Pvt. Ltd., Avantti Medi Clear, Steripure SAS, Europlaz Technologies Limited, Centerpiece Holdings LLC, Midwest Sterilization Corporation, Blue Line Sterilization Services LLC, Johnson And Johnson.

North America was the largest region in the terminal sterilization services market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global terminal sterilization services market report during the forecast period. The regions covered in the terminal sterilization services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the terminal sterilization services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Two main categories of terminal sterilization services include contract sterilization services and sterilization validation services. Contract sterilization services involve providing sterilization services under contract to various companies for the sterilization of their final products. This is achieved through methods such as ethylene oxide sterilization, gamma sterilization, steam sterilization, electron beam radiation sterilization, and x-ray, employing technologies such as gravity, vacuum, steam, forced convection, and natural convection. End users benefiting from terminal sterilization services include hospitals and clinics, pharma and nutraceuticals, medical device manufacturing and packaging, other manufacturing sectors (semiconductors, food, confectionaries, chemicals, and materials), academic research institutes, and other end users.

The terminal sterilization services market research report provides terminal sterilization services market statistics, including global market size, regional shares, competitors with a terminal sterilization services market share, detailed terminal sterilization services market segments, market trends and opportunities, and any further data you may need to thrive in the terminal sterilization services industry. This terminal sterilization services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The terminal sterilization services market includes revenues earned by entities by autoclaving, dry heat sterilization, hydrogen peroxide sterilization, and ethylene oxide sterilization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.